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Available online 16 February 2016The human embryonic stem cell line RCe009-A (RC-5)was derived from a frozen and thawed Day 2 embryo volun-
tarily donated as unsuitable and surplus to requirement for fertility treatment following informed consent under li-
cence from the UK Human Fertilisation and Embryology Authority. RCe009-A carries the common DF508 mutation
on the cystic ﬁbrosis trans-membrane regulator gene associated with the disease cystic ﬁbrosis. The cell line shows
normal pluripotency marker expression and differentiation to the three germ layers in vitro. It has a normal 46XX
female karyotype and microsatellite PCR identity, HLA and blood group typing data are available.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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RCe009-A (RC-5) was derived from a frozen and thawed, pre-im-
plantation genetic diagnosis embryo conﬁrmed to have a heterozygous
cystic ﬁbrosis mutation (DF508 on the CTFR gene). The embryo was re-
ceived as a Day 2 embryo and grown to blastocyst stage. The cell line
was derived by whole embryo outgrowth on mitotically inactivated
human ﬁbroblast (HDF) feeder cells using HDF conditioned medium
and expanded under feeder free conditions.
RCe009-A (RC-5) was shown to be pluripotent by expression of
the pluripotency markers Oct-4, Nanog, SSEA-4, Tra-1-60 and Tra-
1-81, but not the differentiation marker SSEA-1, using immunocyto-
chemistry (Table 1, Fig. 1). By ﬂow cytometric analysis, the expres-
sion of pluripotency makers Tra-1-60, Tra-1-81 and SSEA-4 was
94.8, 93.6% and 94.8%, respectively, but some expression of the dif-
ferentiation marker SSEA-1 (37.3%) was observed (Fig. 2). Differen-
tiation to the three germ layers, endoderm, ectoderm and
mesoderm, was demonstrated using embryoid body formation and
expression of the germ layer markers α-fetoprotein, β-tubulin and
muscle actin (Fig. 3).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 2). Blood group genotyping
gave the blood group AO1 (Table 2).Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding (Fig. 4)
and showed a normal 46XX female genotype. The cell line is free from
mycoplasma contamination as determined by RC-qPCR. Microsatellite
PCR DNA proﬁling for cell identity is available.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Summary of quality control testing and results for RC-5 (RCe009-A).
Classiﬁcation Test Purpose Result
Donor screening HIV 1 + 2
Hepatitis B
Hepatitis C
Donor screening for adventitious agents Negative
Identity Microsatellite PCR (mPCR) DNA Proﬁling to give cell line its signature,
gender/species
Performed
Phenotype Immunocytochemisty To assess levels of staining for the
pluripotency markers
Expression of Oct4, Nanog,
SSEA-4, Tra-1-60 and Tra-1-81
Flow cytometry Assess antigen levels and cell surface markers
commonly associated with hESC
Tra-1-60: 94.8%
Tra-1-81: 93.6%
SSEA-4: 94.8%
SSEA-1: 37.3%
Genotype
(details provided in Table 2)
Blood group genotyping
(DNA analysis)
To establish blood group of the line AO1
Karyology (G-banding) Conﬁrmation of normal ploidy by G-banding 46XX
HLA tissue typing To establish full HLA Type I and II genotype of the line HLA typed Class I and Class II
Microbiology and Virology Mycoplasma Mycoplasma testing by RT-qPCR Negative
Endotoxin Screening for endotoxin levels 1.82 EU/mL
Morphology Photography To capture a visual record of the line Normal
Differentiation potential Embryoid body formation To show differentiation to three germ layers Expression of muscle actin,
β-tubulin and α-fetoprotein
419P.A. De Sousa et al. / Stem Cell Research 16 (2016) 418–422Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A Research
Ethics Committee and local ethics board at participating fertility clinics
and conducted under licence no. R0136 from the UK HFEA with in-
formed donor consent.
Cell culture
Frozen embryos were thawed using Embryo Thawing Pack (Origio
(Medicult), Denmark) using standard techniques and were cultured in
EmbryoAssist (Origio) until Day 3 and BlastAssist (Origio) after Day 3
of development. Embryos were cultured at 36.5–37.5 °C, 5 ± 0.5% CO2,
5 ± 0.5% O2 in drops under parafﬁn oil (Origio) and transferred to
fresh medium at least every 2–3 days.
By Day 8 of development, or when spontaneous hatching occurred,
embryos were placed in derivation conditions consisting of mitoticallyFig. 1. Immunostaining of RCe009-A (RC5) show expression of pluripotency markers Oinactivated neonatal human dermal ﬁbroblasts (HDFs) (ThermoFisher
Scientiﬁc (Cascade Biologics), Paisley, UK) on tissue culture plastic pre-
coatedwith 2 μg/cm2 human laminin (Sigma Aldrich, Dorset, UK) as per
manufacturer's recommendation. If required, assistedhatchingwasper-
formed by removing the zona pellucidae mechanically using Swemed
Cutting tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% FCS
(GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-glutamine
(ThermoFisher Scientiﬁc). HDF were mitotically inactivated using
gamma irradiation at 50GY using a Gammacell Elite 1000 machine.
For use as a feeder layer, irradiated HDFs were plated at 2–
50,000 cells/cm2 in HDF conditioned medium (80% Knockout-DMEM,
20% Knockout serum replacement (KOSR), 1 mM glutamine, 0.1 mM
β-mercaptoethanol, 1% nonessential amino acids, and 4 ng/ml human
bFGF (all ThermoFisher Scientiﬁc) over 24 h intervals over 7 days) sup-
plemented with an additional 24 ng/ml human bFGF. Cells were cul-
tured at 36.5–37.5 °C, 5 ± 0.5% CO2, 5 ± 0.5% O2 and 50% medium
exchanged 6 days a week.
The established cell line was expanded and banked using CellStart
matrix and Stempro hESC Serum Free Medium (ThermoFisherct-4, Nanog, Tra-1-60, Tra-1-81 and SSEA-4, but not differentiation marker SSEA-1.
Fig. 2.RCe009-A (RC-5) was subjected to ﬂow cytometry analysis formarkers of pluripotencywith isotype controls (left hand column) or speciﬁc antibodies for SSEA-1, Tra-1-60 and Tra-
1-81 (top row) or SSEA-4 (bottom row). Percentage staining is indicated in Table 1.
420 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 418–422Scientiﬁc). Passaging was performed mechanically using an EZ passage
tool (ThermoFisher Scientiﬁc). hESC lines were expanded to 25–30
wells of a 6-well plate and cryopreserved in 0.5-1 ml KOSR based cryo-
preservation solution (75% KO-DMEM, 15% Xeno-free KOSR
(ThermoFisher Scientiﬁc) and 10% DMSO (Origen Biomedical, Texas,
USA)) or Cryostor CS10 (Biolife Solution, Washington, USA).
Mycoplasma
Mycoplasma detection was performed using Applied Biosystems
PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™
Mycoplasma Real-Time PCR Detection Kit (ThermoFisher Scientiﬁc
(Applied Biosystems)) according to manufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
manufacturer's instructions. Brieﬂy, an unknown samplewas compared
with a standard curve of known levels of control endotoxin. An assay
was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and the
CV (%) for the standard curve was ≤10%.
Flow cytometry
Human embryonic stem cells were dissociated using Trypsin
(ThermoFisher Scientiﬁc). Non-speciﬁc staining was blocked using
5% goat serum (Sigma) in PBS (Lonza) containing 0.01% Tween-20
(Sigma). Cells were stained with antibodies against SSEA-4, SSEA-1,Fig. 3. In vitro differentiation of RCe007-A (RC-3) to ectoderm (β-tubulin III), mesoderm (mus
counterstained with DAPI (blue).Tra-1-60 and Tra-1-81 (all BD, Oxford, UK), at 250 ng per reaction
followed by Goat F(ab)2 anti-mouse IgM-PE Goat F(ab)2 anti-mouse
IgG3-FITC (1:200; Santa Cruz Biotechnology, Texas, USA). Cells were
analysed using a FACS Aria ﬂow cytometer (BD).
Immunocytochemistry
hESC were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisher Scientif-
ic) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000; Sigma),
muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark), Oct-4 (1:200;
Santa Cruz Biotechnlogy, Texas, USA), Nanog (1:20; R&D Systems,
Abingdon, UK), Tra-1-60, Tra-1-81, SSEA-1 and SSEA-4 (all 1:50; BD)
and secondary antibodies anti-mouse IgG-FITC (1:200; Sigma), anti-
mouse IgG-AlexaFluor 488, anti-goat IgG-AlexaFluor 488, anti-goat IgG-
AlexaFluor-594 and anti-donkey polyclonal AlexaFluor-594 (all 1:200;
ThermoFisher Scientiﬁc). Images were acquired using a Zeiss S100
Axiovert ﬂuorescence microscope or Nikon eC1 confocal microscope.
In vitro differentiation
hESC cells were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
EBs generated in ultra low attachment plates (Corning) for 7 days before
being transferred into EBmedium (20% FBS (GE Healthcare (PAA)), 80%
KO-DMEM 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1% nones-
sential amino acids (all ThermoFisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with 0.5% gel-
atin (Sigma) at 0.1 ml/cm2 for 14 days.cle actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green, cell nuclei are
Table 2
Microsatellite PCR, blood group and HLA tissue typing results for RCe009-A (RC-5).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2 D16S539 1 D16S539 2 D2S1338 1 D2S1338 2
18 18 16 17 9 11 17 21
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2 D21S11 1 D21S11 2 D18S51 1 D18S51 2
X X 13 14 29 30 10 15
D19S433 1 D19S433 2 THO1 1 THO1 2 FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
14.2 15 8 9 21 25 10 10
D5S818 1 D5S818 2 D7S820 1 D7S820 2 D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 12 10 11 8 13 8 11
Blood group genotyping
RhD RhC Rhc RhE Rhe Fy a Fy b Fy GATA
pos neg pos pos pos pos pos neg
Jka Jkb K k M N S S
neg pos neg pos pos pos neg pos
Kp a Kp b Do a Do b ABO
neg pos neg pos AO1
HLA Tissue Typing
HLA Class I Type HLA-A*01, A*32; B*40, B*57; C*02, C*06
HLA Class II Type HLA-DRB1*13; DRB3*02; DQB1*06
Comment B*40 is expressed serologically as B61.
421P.A. De Sousa et al. / Stem Cell Research 16 (2016) 418–422Genomic analysis
All outsourced assayswere carried out under a Quality and Technical
Agreement. DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Manchester, UK) according to manufacturer's recommenda-
tions and provided in recommended quantities to the service providers.Fig. 4. RCe009-A (RC-5) was analysed by Giesma staining of 20 metMicrosatellite PCR, or Short TandemRepeat analysis, was used to de-
termine cell line identity and was carried out by Public Health England.
A proﬁle was obtained for the following core alleles: vWA, D16S539,
Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.aphase spreads and showed a normal 46XX female karyotype.
422 P.A. De Sousa et al. / Stem Cell Research 16 (2016) 418–422Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory
(London, UK) or the Western General Cytogenetics Laboratory
(Edinburgh, UK). Live cells at 60–70% conﬂuency were shipped over-
night in warm containers, ﬁxed and analysed by standard G-banding
analysis. For research grade lines, 20 spreads were analysed.Acknowledgements
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